130 related articles for article (PubMed ID: 36711758)
1. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
medRxiv; 2023 Jan; ():. PubMed ID: 36711758
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
3. Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Feb; ():. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
4. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
[TBL] [Abstract][Full Text] [Related]
5. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
Curkovic NB; Bai K; Ye F; Johnson DB
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
[TBL] [Abstract][Full Text] [Related]
8. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
Duraisamy P; Panicker VV; Jose WM
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
10. Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
Luangnara A; Kiratikanon S; Ketpueak T; Suksombooncharoen T; Charoentum C; Chewaskulyong B; Tovanabutra N; Chiewchanvit S; Nochaiwong S; Chuamanochan M
Front Immunol; 2022; 13():965550. PubMed ID: 36341419
[TBL] [Abstract][Full Text] [Related]
11. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study.
Wan G; Nguyen N; Leung BW; Rashdan H; Tang K; Roster K; Collier MR; Ugwu-Dike PO; Raval NS; Alexander NA; Jairath R; Phillipps J; Amadife M; Zhang S; Gusev A; Chen ST; Reynolds KL; LeBoeuf NR; Kwatra SG; Semenov YR
medRxiv; 2023 Aug; ():. PubMed ID: 37693493
[TBL] [Abstract][Full Text] [Related]
12. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity. A prospective study of 189 patients treated with checkpoint inhibitors in a Spanish tertiary care hospital.
Juan-Carpena G; Martínez Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
Clin Exp Dermatol; 2024 Feb; ():. PubMed ID: 38372424
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
16. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
Nadelmann ER; Yeh JE; Chen ST
JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
[TBL] [Abstract][Full Text] [Related]
18. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.
Nuzzo PV; Adib E; Weise N; Curran C; Stewart T; Freeman D; Nassar AH; Abou Alaiwi S; Bakouny Z; McGregor BA; Choueiri TK; Jain RK; McKay RR; Sonpavde G
Clin Genitourin Cancer; 2022 Aug; 20(4):301-306. PubMed ID: 35614012
[TBL] [Abstract][Full Text] [Related]
19. Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.
Mital R; Otto TS; Savu A; Baumrin E; Cardones AR; Carlesimo M; Caro G; Freites-Martinez A; Hirner JP; Markova A; McLellan BN; Rossi A; Sauder MB; Seminario-Vidal L; Sibaud V; Owen DH; Dulmage BO; Chen ST; Kaffenberger BH
Int J Dermatol; 2023 Aug; 62(8):1020-1025. PubMed ID: 37203799
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
